EterLink

Eterlink is a Japanese biotechnology company specializing in the development of advanced drug delivery systems (DDS) for biopharmaceuticals. Spun out from Kyoto University, the company leverages its proprietary "Eter-Link" technology to facilitate the intracellular delivery of large molecules, including proteins, antibodies, and nucleic acids. This platform addresses a critical bottleneck in drug development by enabling therapeutic agents to access targets located inside the cell, which are often unreachable by conventional biologics. Eterlink's approach focuses on enhancing the cellular uptake and endosomal escape of these molecules, potentially opening new avenues for treating oncology and genetic disorders. The company is currently in the pre-clinical stage, focusing on refining its platform and establishing strategic partnerships.